NAD+ IV vs subcutaneous vs oral — what bioavailability research suggests

The delivery question matters more for NAD+ than for most compounds because of a basic problem with its chemistry. NAD+ is a large, charged dinucleotide. The gastrointestinal environment is not hospitable to it — stomach acid and intestinal enzymes, particularly CD73 and related ectonucleotidases, degrade it efficiently — and the membrane transport machinery in gastrointestinal cells isn't designed to absorb intact NAD+. What gets absorbed through the gut wall after oral NAD+ ingestion is mostly degradation products: nicotinamide, mainly, which then enters the biosynthesis pathway from a point well upstream of NAD+. The molecule you swallowed does not arrive intracellularly as NAD+.

This is the foundational reason the precursor strategy exists. NMN and NR — the upstream precursors — are smaller, more stable molecules that are absorbed more readily and then converted to NAD+ intracellularly through the salvage pathway. When researchers say oral NAD+ "doesn't work," they're not saying you get nothing from it — they're saying the mechanism by which you'd get any NAD+-related benefit from swallowing oral NAD+ is not direct delivery of NAD+ to cells. It's the same indirect route as taking a precursor, but with less efficient absorption and more degradation in transit. This is why essentially all the serious oral NAD+ supplementation research is done with NR or NMN rather than NAD+ itself.

The oral precursor route — NR or NMN in capsule form — is how most people first engage with NAD+ support, and it does genuinely raise blood NAD+. Multiple randomized controlled trials for NR, and a smaller number for NMN, have demonstrated that. The question is one of magnitude and tissue distribution. Blood NAD+ is a proxy for what you're actually interested in: intracellular NAD+ in specific tissues, particularly muscle, liver, and brain. The relationship between blood NAD+ and tissue NAD+ is not perfectly linear, and the clinically relevant question — whether oral precursor doses achievable without significant side effects produce meaningful intracellular NAD+ elevation in the tissues where age-related decline matters most — remains under active investigation.

The dose ranges studied in oral trials for NR run from 250 mg to 2000 mg per day, with 500 mg and 1000 mg being the most common trial doses. NMN trials have used similar ranges. At these doses, blood NAD+ elevations of 40 to 100 percent over baseline have been documented. That sounds like a lot until you realize that NAD+ levels in people in their fifties or sixties may be 40 to 50 percent below what they were in their twenties — meaning a 50 percent elevation from a depressed baseline may still not reach youthful levels, and may not reach the intracellular concentrations in specific tissues that the mouse studies used to produce their effects. This gap between "we raised blood NAD+" and "we replicated the tissue levels in aged mice that were associated with benefit" is honest and worth carrying with you.

IV NAD+ infusions are the approach that sidesteps the absorption question entirely. When NAD+ is delivered intravenously, it enters the bloodstream directly. Plasma NAD+ rises dramatically — to levels not achievable through any oral approach — and the resulting concentration gradient across cell membranes is steep enough that intracellular uptake follows. The pharmacokinetics here are fundamentally different: you're not relying on precursor conversion or salvage pathway capacity; you're flooding the system from the outside in.

The protocols vary, but the most commonly used clinical ranges are 500 to 1500 mg per infusion, delivered over three to eight hours. The longer infusion time is not incidental — it's necessary to manage the subjective experience. People receiving IV NAD+ infusions often describe a characteristic set of sensations during the infusion: warmth that spreads through the chest and face, sometimes an uncomfortable pressure or tightness, heart palpitation-adjacent sensations, and what many describe as a kind of intense, almost restless energy. These sensations are not dangerous at the rates used in clinical protocols, but they're real and they're the reason that pushing the infusion faster than about 100-200 mg per hour tends to intensify them to the point of discomfort. Experienced infusion providers slow the rate when these symptoms emerge; slowing the rate reliably reduces them.

Why does this happen? The honest answer is that the exact mechanism isn't fully characterized, but the leading hypothesis involves NAD+ degradation products during the infusion — particularly nicotinamide — activating receptors in ways that produce these sensations, possibly involving serotonin receptor activity or mast cell involvement. Some infusion providers use adjuncts like B vitamins or magnesium to modulate the experience. The sensations are time-limited, they resolve when the infusion is complete or slowed, and they are not the experience on the other side of the infusion. The typical report after IV NAD+ is quite different: a period of fatigue on the day of or the day after the infusion, followed by a multi-day period of elevated energy, mental clarity, and what people often describe as a brightness or presence of mind that feels distinctly different from stimulant-driven alertness.

This isn't clinical outcomes data — it's patient-reported experience from clinical settings — but it's consistent enough across providers and contexts to be worth naming.

The cost and time burden of IV NAD+ is a genuine constraint. A single session typically costs between $400 and $1000 depending on the provider, the dose, and the location. A 500 mg infusion at a comfortable rate takes three to four hours. A 1000 mg infusion may take six or more. This is not something most people can do weekly; many clinical protocols use it monthly or quarterly, with oral precursors in between as a maintenance strategy. Some providers use a protocol of three to five consecutive infusions for an initial loading phase, then space subsequent infusions out. These protocols are clinical practice, not rigorous trial design, and the evidence base for specific schedules is limited.

Subcutaneous NAD+ — injected under the skin in small volumes, typically 25 to 100 mg per dose — represents an emerging middle ground. The pharmacokinetic rationale is that subcutaneous delivery bypasses gastrointestinal degradation and delivers NAD+ directly into systemic circulation via the subcutaneous tissue and lymphatic drainage, but at a rate and concentration that avoids the intensity of IV delivery. The subjective experience is generally reported as much milder than IV — less warmth, less cardiovascular sensation — partly because the dose is smaller and partly because the absorption is slower and more gradual.

The formal pharmacokinetic data on subcutaneous NAD+ in humans is sparse. The clinical practice of subcutaneous NAD+ microdosing has moved faster than the research characterizing it, which is common in compounded peptide and compound medicine. What exists is largely mechanistic reasoning, practitioner experience, and patient self-report rather than controlled pharmacokinetic studies. The tissue concentrations achieved, the half-life in the subcutaneous compartment, and the comparative efficacy versus IV at equivalent doses are not well-characterized at a data level. That doesn't make it implausible — the pharmacological rationale is sound — but it means the dose calibration and frequency of subcutaneous protocols is more empirical than evidence-derived.

Intramuscular delivery sits between subcutaneous and IV in terms of absorption rate. IM injection delivers NAD+ into vascular muscle tissue, where absorption into systemic circulation is faster than subcutaneous but slower and more controlled than direct IV. Some providers use IM for moderate doses in the 50 to 200 mg range. The practical experience with IM appears to fall between subcutaneous and IV: more noticeable effect onset than subcutaneous, milder than IV, achievable outside a clinic setting with appropriate training and oversight.

The cost differential is stark. Oral NR or NMN at a reasonably studied dose runs $50 to $100 per month. Subcutaneous NAD+ through a compounding pharmacy with provider oversight might run $150 to $400 per month depending on dose and frequency. IV NAD+ at a clinic can cost that much per session or more. The question of whether the superior plasma delivery of IV NAD+ translates proportionally to superior clinical outcomes — given that outcomes data at any delivery route is still incomplete — is not one the current research can answer definitively. Providers who use IV NAD+ clinically argue the subjective response magnitude justifies the cost for appropriate patients. This is a reasonable clinical judgment. It's not the same as a controlled trial showing superiority.

The honest synthesis is this: the delivery route for NAD+ matters significantly, and oral NAD+ itself is the least efficient option at the cellular level — the oral precursor strategy is more rational if oral supplementation is the goal. Among the non-oral routes, IV provides the most direct and substantial elevation of plasma and intracellular NAD+, at the cost of time, money, and a distinct physiological experience during the infusion. Subcutaneous offers a lower-intensity, lower-cost, more accessible alternative with less established pharmacokinetics. The right approach for a given person depends on their baseline, their goals, their access, and a conversation with a prescribing provider who can evaluate their specific situation. What it doesn't depend on is the marketing, which has gotten significantly ahead of the evidence at every delivery route.